National Institutes of Health: Ovarian Neoplasms trials

The registry lists 111 Ovarian Neoplasms studies with National Institutes of Health as lead sponsor. 11 are open to participants now and 41 have results posted.

Early Phase 1 3Phase 1 41Phase 2 50Phase 3 7No phase 18(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• SU5416 and Carboplatin to Treat Ovarian CancerCompletedNCT00006155Phase 1
• Gene Therapy in Treating Patients With Ovarian CancerCompletedNCT00003588Phase 1
• Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian CancerCompletedNCT00002734Phase 1
• A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)CompletedNCT00001938
• Microarray Analysis for Human Genetic DiseaseCompletedNCT00001898
• p53 Vaccine for Ovarian CancerTerminatedNCT00001827Phase 2
• Methods in Education for Breast Cancer GeneticsCompletedNCT00001806Phase 3
• Outcomes of Education and Counseling for BRCA1 TestingCompletedNCT00001468
• A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and CisplatinCompletedNCT00001427Phase 2
• A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian CancerCompletedNCT00001426Phase 2
• A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer PatientsCompletedNCT00001272Phase 1